Giapreza: Clinical Trials

11 trials of Giapreza, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 active not recruiting, 2 withdrawn, 1 not yet recruiting. 6 Phase 4, 4 Phase 2, 1 Early Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 46Completed 2, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 24Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1
Early Phase 11Active not recruiting 1
Phase 31Active not recruiting 1

Follow Giapreza: new trials by email Literature Review of Giapreza trials Research Report on Giapreza

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V)
Angiotensin II (Giapreza®) - Vasoplegic Shock, Cardiopulmonary Bypass
Phase 4Not yet recruitingMethodist Healthcare System of San Antonio3292026-07-012026-06-26
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Angiotensin II (Giapreza®), Yttrium-90 radioembolization - Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult
Phase 2RecruitingNiek Wijnen152026-01-012026-03-30
Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance
Giapreza - Septic Shock, Cirrhosis
Early Phase 1Active not recruitingThe Cleveland Clinic302024-11-152026-05-05
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
Angiotensin II and hydrocortisone sodium succinate - Septic Shock, Shock
Phase 4UnknownKingman Regional Medical Center502023-12-042024-05-23
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
Angiotensin II - Septic Shock, Vasodilatory Shock
Phase 4CompletedUniversity of New Mexico422023-04-172026-07-02
Angiotensin II in Liver Transplantation
Angiotensin II, Saline - Liver Transplant; Complications, Vasoplegia
Phase 2 / Phase 3Active not recruitingUniversity of California, San Francisco502022-06-282026-03-20
Angiotensin II for Distributive Shock
Angiotensin II, Placebo - Distributive Shock
Phase 4TerminatedNorthwestern University22022-06-012026-04-13
Angiotensin II vs. Vasopressin in Septic Shock
Angiotensin II, Vasopressin - Septic Shock
Phase 4WithdrawnUniversity of New Mexico2022-01-032024-03-15
Angiotensin 2 for Hepatorenal Syndrome
Angiotensin II, Midodrine, Octreotide - Hepatorenal Syndrome, Cirrhosis
Phase 2WithdrawnUniversity of California, Los Angeles2021-07-012024-03-06
Angiotensin II in General Anesthesia
Angiotensin II - Hypertension
Phase 4CompletedWake Forest University Health Sciences322019-10-032025-08-24
A Study of LJPC-501 in Pediatric Patients With Hypotension
Angiotensin II - Catecholamine-resistant Hypotension (CRH), Distributive Shock
Phase 2CompletedLa Jolla Pharmaceutical Company22018-02-112018-08-07

Conditions studied

Shock, Septic (4)  ·  Acute Kidney Injury (3)  ·  Fibrosis (3)  ·  Vasoplegia (3)  ·  Sepsis (2)  ·  Carcinoma, Hepatocellular (1)  ·  Diabetes Insipidus (1)  ·  Hepatorenal Syndrome (1)  ·  Hypertension (1)  ·  Hypotension (1)  ·  Liver Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Shock (1)  ·  Systemic Inflammatory Response Syndrome (1)

Sponsors

University of New Mexico (2)  ·  Kingman Regional Medical Center (1)  ·  La Jolla Pharmaceutical Company (1)  ·  Methodist Healthcare System of San Antonio (1)  ·  Niek Wijnen (1)  ·  Northwestern University (1)  ·  The Cleveland Clinic (1)  ·  University of California, Los Angeles (1)  ·  University of California, San Francisco (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (8)  ·  Netherlands (1)

Top investigators

Joao P Teixeira, MD (2)  ·  Nathan D Nielsen, MD MSc (2)  ·  Choy Lewis, MD (1)  ·  Michael P Bokoch, M.D., Ph.D. (1)  ·  Rohesh Fernando, MD (1)  ·  Siddharth Dugar, M.D. (1)  ·  Tyson Dietrich, PharmD (1)

Results publications

PMID 24466071, PMID 37984940

NIH funding

2025 (1), UL1TR001449 (1)